Annalee Armstrong

With much still to discover in the massive world of radiopharmaceuticals, Novartis will take a deep dive into the unknown with Mariana Oncology in a $1 billion upfront acquisition.

The next frontier for pharma in the obesity space is improving the quality of weight loss.

Mark your calendars: Eli Lilly will come before the FDA’s advisory committee to discuss Alzheimer’s disease medicine donanemab June 10.

If your child is in a clinical trial for what could be a ground-breaking treatment to restore hearing, as a parent, you’re going to notice the changes before a clinical investigator ever does.

After Orchard Therapeutics' gene therapy for a rare genetic disease was approved in March, Peter Marks, M.D., Ph.D., received a simple email from Commissioner Robert Califf, M.D.

Accelerated approval—controversial, yes—but absolutely necessary for small, pre-revenue biotechs trying to find new treatments for small patient populations.

The list of biotechs worthy is sparse Through all of the biotechs we need help to parse We're looking for the best, the strongest

Phil Gregory's new gig looks a whole lot like his old gig. It's just that, under the umbrella of Regeneron, things have gotten a bit bigger.

If a gene therapy is approved in the U.S., patients in Brazil can sue their government to get it cleared for use there.

Linda Burkly, Ph.D., was 37 years into a career at Biogen when Editas Medicines CEO Gilmore O’Neill—himself an alum of the neurological disease-focused big biotech—came knocking.